| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,260,000 |
| Market
Cap: |
11.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5036 - $0.5036 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile PDS Biotechnology is a clinical-stage immunotherapy company developing a pipeline of molecularly targeted immunotherapies designed to overcome the limitations of existing immunotherapy and vaccine technologies. Co. owns the proprietary T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune®, for treatments in oncology and Infectimune™, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Co. is developing targeted product candidates to treat cancers including Human Papillomavirus associated cancers, melanoma, colorectal, lung, breast and prostate cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bedu-Addo Frank |
President/CEO |
• • – |
2022-12-02 |
4 |
D |
$9.78 |
$1,713,300 |
D/D |
(175,184) |
690,866 |
|
- |
|
| Bedu-Addo Frank |
President/CEO |
• • – |
2022-12-02 |
4 |
OE |
$6.57 |
$1,442,345 |
D/D |
219,535 |
866,050 |
|
- |
|
| Hill Mathew C |
Chief Financial Officer |
• • – |
2021-12-13 |
4 |
B |
$9.00 |
$1,800 |
I/I |
200 |
4,075 |
0.01 |
- |
|
| Hill Mathew C |
Chief Financial Officer |
• • – |
2021-12-13 |
4 |
B |
$8.90 |
$26,060 |
D/D |
2,900 |
3,875 |
0.01 |
- |
|
| Hill Mathew C |
Chief Financial Officer |
• – – |
2021-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
975 |
|
- |
|
| Bloomquist Delyle W |
See Remarks |
• • – |
2021-06-16 |
4 |
B |
$9.88 |
$98,778 |
D/D |
10,000 |
193,888 |
0.01 |
- |
|
| Bloomquist Delyle W |
See Remarks |
• • – |
2021-06-16 |
4 |
OE |
$5.99 |
$17,790 |
D/D |
2,970 |
183,888 |
|
- |
|
| Glover Steve C |
|
• • – |
2021-06-15 |
4 |
B |
$8.50 |
$49,997 |
D/D |
5,882 |
63,790 |
0.01 |
- |
|
| Freitag Gregory Gene |
|
• • – |
2021-06-15 |
4 |
B |
$8.50 |
$49,997 |
D/D |
5,882 |
46,153 |
0.01 |
- |
|
| Bedu-Addo Frank |
President/CEO |
• • – |
2021-06-15 |
4 |
D |
$12.86 |
$349,355 |
D/D |
(27,166) |
646,515 |
|
- |
|
| Bedu-Addo Frank |
President/CEO |
• • – |
2021-06-15 |
4 |
OE |
$6.57 |
$349,353 |
D/D |
53,174 |
673,681 |
|
- |
|
| Van Voorhees Seth |
Chief Financial Officer |
• • – |
2021-06-15 |
4 |
B |
$8.50 |
$150,000 |
D/D |
17,647 |
17,647 |
0.01 |
- |
|
| Ali-Jackson Kamil |
|
• • – |
2021-06-15 |
4 |
B |
$8.50 |
$99,994 |
D/D |
11,764 |
11,764 |
0.01 |
- |
|
| Sykes Richard |
|
• • – |
2020-02-14 |
4 |
A |
$1.30 |
$500,000 |
D/D |
384,615 |
445,108 |
|
- |
|
| Saik Andrew |
Chief Financial Officer |
• • – |
2020-02-14 |
4 |
A |
$1.30 |
$49,920 |
D/D |
38,400 |
42,549 |
|
- |
|
| Glover Steve C |
|
• • – |
2020-02-14 |
4 |
A |
$1.30 |
$49,920 |
D/D |
38,400 |
57,908 |
|
- |
|
| Freitag Gregory Gene |
|
• • – |
2020-02-14 |
4 |
A |
$1.30 |
$49,920 |
D/D |
38,400 |
40,271 |
|
- |
|
| Sykes Richard |
|
– • – |
2019-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
60,493 |
|
- |
|
| Freitag Gregory Gene |
|
– • – |
2019-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,871 |
|
- |
|
| Conn Gregory |
Chief Scientific Officer |
• – – |
2019-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
115,545 |
|
- |
|
| Bloomquist Delyle W |
|
– • • |
2019-03-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
605,023 |
|
- |
|
| Bloomquist Delyle W |
|
– • • |
2019-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
180,918 |
|
- |
|
| Bedu-Addo Frank |
President/CEO |
• • • |
2019-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
620,507 |
|
- |
|
| Macdonald R. Loch |
Director |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
580,602 |
|
- |
|
| Crane Rosemary A |
Director |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
122 Records found
|
|
Page 1 of 5 |
|
|
